BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.

doi:10.1038/modpathol.2013.206

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Jul 2014

Goeppert Benjamin, Frauenschuh Lena, Renner Marcus, Roessler Stephanie, Stenzinger Albrecht, Klauschen Frederick, Warth Arne, Vogel Monika Nadja, Mehrabi Arianeb, Hafezi Mohammadreza, Boehmer Katja, von Deimling Andreas, Schirmacher Peter, Weichert Wilko, Capper David

Abstract excerpt

BRAF mutations have emerged as an important predictive biomarker for metastasized melanoma. Other types of cancer may also benefit from BRAF mutation-targeted therapies. In biliary tract cancer, reported BRAF mutation rates are highly controversial, ranging from 0 to 33% in adenocarcinoma of the gallbladder and 0 to 22% in cholangiocarcinoma. We here analyzed tissue microarrays of a large cohort of biliary tract...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bile Duct Neoplasms

Share to Bile Ducts, Intrahepatic

Share to Cholangiocarcinoma

Share to Immunohistochemistry

Share to Mutation Rate

Share to Proto-Oncogene Proteins B-raf

Share to Tissue Array Analysis

Source

Open in PubMed

Identifiers

PMID: 24309328
DOI: 10.1038/modpathol.2013.206

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.PMID 24309328Read ↗

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.Semantic proximity Read ↗

Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.Semantic proximity Read ↗

Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.Semantic proximity Read ↗

No evidence for BRAF-V600E mutations in gastroeosophageal tumors: results from a high-throughput analysis of 534 cases using a mutation-specific antibody.Semantic proximity Read ↗

The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.Semantic proximity Read ↗

Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.Semantic proximity Read ↗

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens.Semantic proximity Read ↗

BRAF V600E mutations in bile duct adenomasSemantic proximity Read ↗

Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review.Semantic proximity Read ↗

KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients.Semantic proximity Read ↗

BRAF V600E-mutant intrahepatic cholangiocarcinoma treated successfully with encorafenib, binimetinib, and cetuximabSemantic proximity Read ↗

BRAF V600E mutation-specific antibody: A review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.